FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 361:2094-2096 November 19, 2009 Number 21 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

Aberrant activation of the hedgehog pathway has been observed in multiple human cancers, including pancreatic cancer. For this reason, several small-molecule inhibitors of the pathway have been advanced to clinical trials to evaluate their efficacy in treating various solid cancers, as recently described in the Journal by Von Hoff et al.¹ Another recent study, by Olive and colleagues,² suggests that pancreatic cancer is a particularly good candidate for experimental treatment with hedgehog inhibitors. In the absence of ligands, such as sonic hedgehog (SHH), the membrane receptor patched (PTCH) blocks the smoothened receptor (SMO), repressing its activity. The binding of the . . . [Full Text of this Article]

Source Information

From the Clinical Research Program, Centro Nacional de Investigaciones Oncológicas, Madrid (M.H.); and the Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins University School of Medicine, Baltimore (A.M.).

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2010 Massachusetts Medical Society. All rights reserved.